Loading...
Evidence indicates that women are more likely than men to develop Alzheimer disease (AD) due to their longer lifespan and hormonal attenuation at menopause. In this longitudinal cohort study, researchers assessed the effect of postmenopausal hormonal therapy (HT) on risk for AD in 8195 Finnish women (baseline age range, 47–56) who completed questionnaires every 5 years from study entry in 1989 until 2009. Use of HT was determined by self-report and registry data, which were available 7 years after baseline and included information on HT preparation (i.e., estrogen-only or combined estrogen and progesterone). AD diagnoses were defined based on published criteria; incident cases were verified with a prescription reimbursement register. Women …